{"filings":[{"id":94207,"accession_number":"0001493152-26-020939","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Biotricity exchanges common, options, warrants for Series C preferred with 40 votes per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14.14M common shares, 3.99M options, and 1.44M warrants exchanged for 1.96M Series C shares at a 10:1 ratio.","Series C carries 40 votes per share; converts into 59.6% of common upon a $15M+ qualified financing.","If no qualified financing by March 31, 2028, each Series C converts to 10 common shares.","Exchange holders include officers and directors; transaction is exempt under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106405,"accession_number":"0001493152-26-007369","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.","Net loss $1.1M ($0.042 per share) vs $1.3M ($0.054 per share) prior year.","Third consecutive quarter of positive EBITDA and net operating income.","Recurring TaaS revenue $3.6M (91.2% of total); customer retention 90%+.","FDA clearance for AI clinical model expected in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.099,"consensus_revenue_estimate":null,"consensus_revenue_actual":11747607.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122760,"accession_number":"0001493152-25-024061","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.","Net loss $0.77M ($0.03/sh) vs $1.7M ($0.07/sh), a 53% improvement.","Recurring TaaS technology fees $3.5M, 88.7% of total revenue.","Regulatory progress in Canada, Saudi Arabia, and Argentina; GPOs covering 90% of U.S. hospitals.","CEO cites AI-driven automation and Biocore Pro adoption as growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.057,"consensus_revenue_estimate":null,"consensus_revenue_actual":7759788.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175388,"accession_number":"0001493152-25-007938","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q3 FY25 revenue $3.6M (+21.7% YoY); net loss down 56.7% to $1.32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross margin improved to 76.4% from 72.9% YoY; recurring tech fees 94% of revenue at 81.4% gross profit.","Recurring Technology Fees rose 21.8% YoY to $3.39M; pure SaaS revenue up 22%.","SG&A reduced 20.5% to $2.38M from $3.0M; positive cash flow from operations second consecutive quarter, up 114.5% sequentially.","Net loss per share improved to $0.054 from $0.339 in Q3 FY24."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.498,"consensus_revenue_estimate":null,"consensus_revenue_actual":10087697.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192328,"accession_number":"0001493152-24-046908","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.","Net loss decreased 57% to $1.65M ($0.073/share) from $3.88M in Q2 FY24.","Recurring tech fees $3.06M (+12.2%), 94% of total revenue; flat fee portion up 34%.","Achieved positive cash flow on current operating basis in September; expects continued improvement.","SG&A cut 35.5% to $2.25M; total operating expenses down 34% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.469,"consensus_revenue_estimate":null,"consensus_revenue_actual":6468589.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208807,"accession_number":"0001493152-24-032861","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biotricity shareholders reject proposal to issue $6.6M in common stock upon Series B conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held August 15, 2024; all four director nominees elected.","Ratification of SRCO Professional Corporation as independent auditor approved with 12.24M votes for.","Proposal to issue up to $6.6M in common stock upon Series B Preferred conversion rejected (1.4M for, 10.9M against).","Elected directors: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, and Jainal Bhuiyan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208806,"accession_number":"0001493152-24-030615","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq delisting notice; trading suspended August 5, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist Biotricity's common stock; trading suspended at open Aug 5, 2024.","Non-compliance with minimum $35M market value of listed securities (MVLS) rule; compliance deadline extended to July 29, 2024.","Company expects stock to be quoted on OTC Pink under symbol BTCY; also applied to OTCQB.","Company has 15 days to request review of Panel's decision by Nasdaq Listing and Hearing Review Council."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208805,"accession_number":"0001493152-24-029939","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq bid price deficiency notice; 180-day cure period to Jan 22, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days triggers Nasdaq Listing Rule 5550(a)(2) deficiency.","Company has until January 22, 2025 to regain compliance with minimum $1.00 closing bid for 10 consecutive days.","If non-compliant by Jan 22, may receive additional 180-day period to cure, subject to other listing standards.","Biotricity intends to monitor bid price and consider available options, including a reverse stock split.","No immediate impact on Nasdaq listing or trading of BTCY common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208804,"accession_number":"0001493152-24-028050","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Biotricity closes second tranche of Series B Preferred Stock private placement for $500,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing of 55 shares of Series B Convertible Preferred Stock at $9,090.91/share for gross proceeds of $500,000.","Combined with June 24 first closing (55 shares), total gross proceeds $1M from 110 shares.","Company must seek stockholder approval by August 15, 2024 for conversion-related matters.","Shares sold under Regulation D exemption; unregistered securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208803,"accession_number":"0001493152-24-027090","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biotricity shareholders approve non-public securities issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held July 12, 2024 approved issuance of securities in one or more non-public offerings.","11,152,302 votes for (98.2%), 195,450 against (1.7%), 10,626 abstain (0.1%).","Approval enables management to conduct private placements without further shareholder vote.","No specific offering amount, price, or timing disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226584,"accession_number":"0001493152-24-024888","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Biotricity raises $500K in Series B Preferred placement; up to $1.5M additional","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 55 Series B Preferred shares at $9,090.91 each for gross proceeds of $500,000 on June 21, 2024.","Potential additional closings up to $1,500,000 through December 31, 2024 at investor's sole discretion.","Series B Preferred carries 8% cumulative dividend (15% on triggering event), convertible at $3.50/share.","Alternate conversion price at 80% (or 70% if suspended/delisted) of lowest VWAP during measuring period.","Company must seek stockholder approval by August 15, 2024; registration rights penalty of 100,000 common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226583,"accession_number":"0001493152-24-023126","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Biotricity issues 8.95M common shares on conversion of Series A Preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 8,952,172 common shares to investors upon conversion of 6,104 Series A Preferred shares plus accrued dividends and fees.","Shares were issued on June 4, 2024 under Section 4(a)(2) exemption; not registered with SEC.","The filing was made on June 7, 2024, reporting the unregistered sale of equity securities.","Conversion of preferred stock dilutes existing common shareholders by adding 8.95M shares to outstanding count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226582,"accession_number":"0001493152-24-021454","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Biotricity amends ATM offering to raise up to $2.68M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to March 2022 ATM agreement with H.C. Wainwright for up to $2,684,644 of common stock.","New registration statement on Form S-3 (File 333-279226) effective May 15, 2024, governs the offering.","Wainwright continues as sales agent; settlement cycle shortened to T+1 per updated rule.","Company adds representation that it is not an investment company under the 1940 Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226581,"accession_number":"0001493152-24-020909","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Biotricity raises $645,455 in third closing of Series B Preferred; total $2M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 71 shares of Series B Convertible Preferred to Ionic Ventures for $645,455 on May 15, 2024.","Combined with prior closings, total 220 Series B shares sold for $2M gross proceeds.","Filed amendment to Form S-3 to register 2,095,238 common shares issuable upon conversion.","Side letter waives 30-day limit on additional closings; company must deliver CA good-standing certificate within 10 days.","Stockholder approval required if conversions exceed Nasdaq rules; meeting to be held within 75 days of triggering event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226580,"accession_number":"0001493152-24-017744","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["3.01","3.02","8.01","9.01"],"status":"ready","headline":"Biotricity faces Nasdaq delisting for missing annual meeting; closes $354k private placement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Biotricity on May 1, 2024 of non-compliance with annual meeting rule; additional delisting basis.","Company must respond to Nasdaq Hearings Panel by May 8, 2024; intends to hold meeting as soon as practicable.","On April 30, 2024, closed second tranche of private placement: 39 Series B Preferred shares for $354,545.","Registration Rights Agreement filed; failure to file or obtain effectiveness triggers 100,000 common shares per event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226579,"accession_number":"0001493152-24-015713","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Nasdaq panel grants Biotricity continued listing subject to milestones by July 29, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Panel granted listing continuation after hearing on April 9, 2024.","Conditions include increasing outstanding shares via stock offerings and convertible conversions.","Company must receive shareholder approval for certain actions.","Biotricity must regain compliance with all Nasdaq listing requirements by July 29, 2024.","Previously received delisting notice for MVLS below $35M for 30 consecutive days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226578,"accession_number":"0001493152-24-012898","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Biotricity amends Series B Preferred Stock to remove voting rights; approved by holder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Certificate of Designations removes voting rights of Series B Preferred Stock (non-voting except as required by law).","Series B Preferred Stock: 600 shares designated at $10,000 stated value, cumulative 8% dividend (15% on Triggering Event).","Initial conversion price $3.50; alternate conversion at 80% of lowest VWAP (70% if delisted/reverse split).","Conversion capped at 4.99% beneficial ownership per holder and 19.9% of common stock absent shareholder approval.","Holder of outstanding Series B Preferred Stock approved amendment via written consent on April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245574,"accession_number":"0001493152-24-011344","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Biotricity raises $1M in private placement of Series B Preferred Stock, with option for additional $1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1M from sale of 110 Series B Convertible Preferred shares at $9,090.91 each.","Company has 30-day option to require second closing for additional $1M (110 more shares).","Series B Preferred Stock: 8% cumulative dividend (15% upon triggering event), initial conversion price $3.50, alternate conversion at 80% of lowest VWAP.","Registration rights agreement requires filing registration statement within 45 days; failure triggers issuance of 100,000 common shares.","Voting agreement with certain stockholders to support Nasdaq-required stockholder approval for conversion shares issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245573,"accession_number":"0001493152-24-004806","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq delisting determination for failure to meet MVLS requirement; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting letter on Jan 30, 2024, for not regaining compliance with $35M MVLS requirement by Jan 29, 2024.","Trading suspension on Nasdaq Capital Market set for Feb 8, 2024, unless the company appeals.","Company plans to request a hearing before the Nasdaq Hearings Panel to appeal and present a compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263038,"accession_number":"0001493152-23-039557","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Biotricity issues $1M convertible note with 12% interest, 18-month maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1,000,000 unsecured convertible preferred note to an investor.","Note bears 12% annual interest, payable monthly in cash.","Maturity 18 months; prepayable at 15% discount to 10-day VWAP; conversion at 20% discount to Qualified Financing price or 15% discount to VWAP at maturity.","Note issued in reliance on Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280241,"accession_number":"0001493152-23-033139","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Biotricity raises $2M via Series B Convertible Preferred Stock at $3.50 conversion price, 8% dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2,000,000 from sale of 220 Series B Preferred shares at $9,090.91 per share.","Series B Preferred carries 8% cumulative dividend, increasing to 15% upon a triggering event.","Initial conversion price set at $3.50 per share; alternate conversion at 80% of lowest VWAP.","Company may redeem shares at 110% of stated value; holders can force redemption upon a trigger event.","Institutional investor subject to 4.99% beneficial ownership cap; shareholder vote may be needed if conversion exceeds 19.9% of outstanding common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280240,"accession_number":"0001493152-23-029242","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q1 FY2024 revenue up 46.9% to $3.0M; net loss improves 28% to $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.02M, up 46.9% YoY; recurring technology fees $2.8M, up 47% YoY.","Gross margin improved to 63.5% from 59.6%; SG&A reduced 22% to $3.5M.","Net loss improved 28% to $3.6M ($0.069 per share) from $5.0M ($0.098 per share).","Customer retention ~98%; expanding sales network across 35 states with >2,500 cardiologists.","Management focuses on path to profitability and AI development with Amazon and Google."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.069,"consensus_revenue_estimate":null,"consensus_revenue_actual":3020765.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280239,"accession_number":"0001493152-23-026879","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq deficiency letter for MVLS below $35M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Aug 1, 2023, Biotricity received Nasdaq notice: MVLS < $35M for 30 consecutive business days.","No immediate delisting effect; company has 180 days (until Jan 29, 2024) to regain compliance.","To regain compliance, MVLS must close at ≥ $35M for a minimum of 10 consecutive business days.","Company intends to monitor market value and may consider available options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280238,"accession_number":"0001493152-23-025121","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biotricity regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on July 18, 2023 confirming compliance with Rule 5550(a)(2).","Previous deficiency notification was received on January 20, 2023 for bid price below $1.00.","Nasdaq has closed the matter; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280237,"accession_number":"0001493152-23-023428","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["2.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Biotricity FY23 revenue up 26% to $9.64M, net loss narrows; 1:6 reverse split effective July 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY23 revenue grew 26% YoY to $9.64M; net loss decreased 35% to $19.5M.","Recurring Technology Fees rose 49% to $8.8M, 71% gross margin; blended margin 57%.","Q4 revenue $2.74M (+28% YoY); net loss $4.9M vs $6.0M a year ago.","1-for-6 reverse split to maintain Nasdaq $1 minimum bid; shares reduce to ~8.5M.","Company targets positive cash flow by end of CY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298772,"accession_number":"0001493152-23-018125","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Biotricity raises ~$1.22M net through convertible notes with 15% interest and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Raised $1,218,930 net proceeds from $1,387,700 principal amount convertible notes at 15% interest, maturing one year from final closing.","Notes convertible after 6 months at lower of 75% of 5-day VWAP or 80% of next qualified financing price.","Investors received 4-year warrants exercisable at 200% of VWAP; exercise price adjusts if stock sold below.","Shareholder approval obtained March 31, 2023, per Nasdaq rules for potential >20% issuance.","Paulson Investment Company acted as placement agent with 10% cash fee and 8% warrant coverage plus $25K expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298771,"accession_number":"0001493152-23-010668","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Biotricity shareholders approve 2023 equity plans, reverse split up to 1:10, and $10M convertible note issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved 2023 Equity Incentive Plan reserving 5M shares plus any unissued from 2016 plan (15.7M votes for).","Authorized reverse stock split within 1:2 to 1:10 ratio, with Board discretion to implement within one year (27.5M for).","Approved potential issuance of up to $10M common stock upon conversion of convertible notes (17.3M for, 629.8K against).","Ratified SRCO Professional Corporation as independent auditor for FY ending March 31, 2023 (28.7M for).","Directors elected: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, Chester White."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318961,"accession_number":"0001493152-23-002805","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Biotricity receives $2M from investor, plans 18-month promissory note at 10% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $2M in cash from an existing investor on January 23, 2023.","Expects to issue an 18-month promissory note with 10% accrued interest.","Final documentation is being finalized; note will contain customary provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318960,"accession_number":"0001493152-23-002082","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq letter on Jan 20, 2023: closing bid price below $1.00 for 30 consecutive days.","Company has until July 19, 2023 to regain compliance with Bid Price Rule.","To regain compliance, bid must close at $1.00+ for 10 consecutive business days.","If not compliant by deadline, Nasdaq may delist; company may consider reverse stock split.","No immediate effect on listing or trading of BTCY common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337189,"accession_number":"0001493152-22-032857","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q2 FY2023 revenue $2.4M, up 14% sequentially; net loss $4.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.4M, up 14% QoQ; gross profit $1.3M (54% margin).","Net loss $4.9M ($0.094 per share) for quarter ended Sept 30, 2022.","Bioheart monitor won TIME's Best Inventions 2022; awarded $250K NIH grant.","Surpassed 2 billion recorded heartbeats for AFib; launched Biocare Cardiac Disease Management Solution.","Maintained 95%+ customer retention; new distribution partnerships signed."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.153,"consensus_revenue_estimate":null,"consensus_revenue_actual":4437441.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354569,"accession_number":"0001493152-22-023263","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity reports Q1 FY2023 revenue $2.1M, net loss $5M, launches Biotres and Bioheart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.1M; gross margin 60% consistent with FY22; net loss $5M ($0.098/sh); adjusted loss $0.085/sh.","Launched Biotres wireless holter patch after FDA clearance; also launched Biokit and Bioheart.","Expanded physician network to 29 states with over 2,000 physicians using products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.098,"consensus_revenue_estimate":null,"consensus_revenue_actual":2056052.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354568,"accession_number":"0001493152-22-022061","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Biotricity directors resign; Chester White appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patricia Kennedy resigned from board and audit/nominating committees effective Aug 5, 2022.","Norman Betts resigned from board and audit committee effective Aug 5, 2022.","Chester White appointed to board on Aug 11, 2022 to fill Kennedy vacancy; no committee assignments yet.","White has experience in fund management, venture capital, and technology innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354567,"accession_number":"0001493152-22-019487","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity reports FY22 revenue $7.7M (+126% YoY); Q4 revenue $2.15M (+81%); net loss $30.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY22 revenue $7.7M (+126% YoY); gross margin improved to 60% from 38% in FY21.","Q4 FY22 revenue $2.15M (+81% YoY); gross margin 67% vs 60% in Q4 FY21.","FY22 net loss $30.2M ($0.665 per share); adjusted loss per share $0.48.","Cash $12M at March 31, 2022; closed $12M non-convertible debt and extinguished $1.6M legacy debt.","Expanded network to 300+ centers, 1,500 cardiologists; launched Biotres, Bioheart, Biokit after FDA clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.098,"consensus_revenue_estimate":null,"consensus_revenue_actual":2056052.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372555,"accession_number":"0001493152-22-012395","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biotricity director Stephen Salmon resigns; Ronald McClurg appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Salmon resigned from board and compensation committee effective May 2, 2022; no disagreement cited.","Ronald McClurg appointed on May 4, 2022 to fill vacancy; will receive standard non-employee director compensation.","McClurg was VP Finance & Administration/CFO of Incisive Surgical from 2003-2019; consultant since 2020.","No material transaction interests or committee assignments disclosed for McClurg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391365,"accession_number":"0001493152-22-007463","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Biotricity signs at-the-market offering agreement for up to $50 million common stock","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Enters ATM agreement with H.C. Wainwright to sell up to $50M of common stock from time to time.","Wainwright receives 3% commission on gross proceeds; Company reimburses up to $50K expenses.","Sales via 'at the market' offerings on Nasdaq; no obligation to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391364,"accession_number":"0001493152-22-004799","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q3 FY22 revenue $1.93M (+93% YoY); net loss $7.34M, cash $16.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.93M, up 93% YoY and 7% sequentially; SG&A rose only 40%.","Net loss $7.34M ($0.15/share); adjusted net loss $6.0M ($0.12/share) excluding $1.34M derivative expenses.","Cash position of $16.8M at quarter-end is the highest ever; completed $12M non-dilutive debt financing.","FDA clearance of Biotres expands TAM from $1B to $5.7B; Bioheart direct-to-consumer launched at $199.","Company reiterates expectation for full-year triple-digit revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5501527.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409563,"accession_number":"0001493152-21-032595","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-12-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Biotricity borrows $12M at LIBOR+10.5%, issues 57,536-share warrant to SWK Funding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $12M from SWK Funding LLC at LIBOR plus 10.5% interest, maturing Dec 21, 2026.","Interest-only payments for first 24 months (extendable to 36); then principal amortization with 40% balloon at maturity.","Issued warrant to purchase 57,536 shares at $6.26/share, expiring Dec 21, 2028.","Origination fee of $120k paid; exit fee of $600k due at termination.","Obligations secured by all assets and intellectual property of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409562,"accession_number":"0001493152-21-030839","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biotricity CEO letter cites record Q2 revenue of $1.81M (+143% YoY), sets 2022 goals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record quarterly revenue of $1.81M for Q2 FY2022 ended Sep 30, 2021, up 143% YoY, tenth consecutive triple-digit growth quarter.","Recent uplisting to Nasdaq to attract larger investor pool and increase liquidity.","Introduced Biokit, a 3-device personal medical kit for integration into Biotricity ecosystem.","Product roadmap includes Bioflux, Biotres, Biocare Telemed, and Bioheart.","2022 goals: launch new cardiac monitoring solutions and software services to become turnkey cardiac health provider."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409561,"accession_number":"0001493152-21-030673","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biotricity publishes 2021 shareholder letter with milestones and 2022 goals","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Shareholder letter published on company website on December 6, 2021.","Letter describes recent milestones and outlines goals for 2022.","No specific financial figures or operational metrics disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409560,"accession_number":"0001493152-21-027370","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q2 FY2022 revenue $1.81M (+143% YoY); net loss $11M includes $5.46M one-time costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.81 million, up 143% year-over-year; gross margin 62%.","Net loss $11.0M ($0.256/sh); adjusted net loss $5.2M ($0.128/sh) excluding $5.46M Nasdaq up-listing costs.","Ended quarter with $11.7 million cash, strongest balance sheet ever.","Announced Biokit personal medical device kit for home-use cardiac monitoring; commercial launch planned Q1 2022.","Revenue impacted by hurricanes and COVID clinic closures in southern US; expects recapture in subsequent months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3571419.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428478,"accession_number":"0001493152-21-022550","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biotricity announces partial exercise of underwriter's option for additional 382,331 shares; total proceeds ~$16M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriter exercised option to purchase 382,331 additional common shares at public offering price.","Total shares sold in offering increased to 5,382,331 generating $16M gross proceeds.","Partial exercise is final; underwriter will not purchase additional shares.","Offering closed on August 30, 2021; H.C. Wainwright acted as sole book-runner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428477,"accession_number":"0001493152-21-022396","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biotricity CEO to present at H.C. Wainwright conference; reiterates prior results","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["CEO Waqaas Al-Siddiq will present on-demand Sept 13-15 at H.C. Wainwright 23rd Annual Global Investment Conference.","Press release reiterates previously announced FY22-1Q revenue growth of 290% YoY and ~49% sequentially.","Also recaps recently completed $15M equity raise and Nasdaq listing, both previously disclosed.","No new financial guidance or material operational updates provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428476,"accession_number":"0001493152-21-021710","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-08-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Biotricity raises $15M in underwritten public offering, lists on Nasdaq Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 5M shares at $3.00/share for ~$15M gross proceeds; H.C. Wainwright sole book-runner.","Closing on August 30, 2021; underwriter partially exercised over-allotment for 48,000 additional shares.","Shares began trading on Nasdaq Capital Market on August 26, 2021 under ticker BTCY.","Net proceeds to be used for general corporate purposes, including working capital and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428475,"accession_number":"0001493152-21-020445","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q1 revenue $1.76M, up 290% YoY, 9th consecutive triple-digit growth quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.76M for Q1 FY2022, up 290% vs. Q1 FY2021; sequential growth 49%.","Operating expenses $4.2M, up only 17% YoY; R&D spend $590K, up 39%.","Company projects continued revenue growth into FY2023; awaiting FDA approval for Biotres holter product.","Gross margin or net income figures not disclosed; Company remains early-stage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1764110.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428474,"accession_number":"0001493152-21-016465","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2021-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity issues preliminary Q1 FY2022 revenue guidance: up >45% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for Q1 ended June 30, 2021 expected to increase >45% sequentially and >280% YoY.","This would be the 9th consecutive quarter of revenue growth.","Customer base expanded to 23 states from 17 states nine months ago.","CEO cites accelerating sequential growth, high correlation between devices and TaaS revenue.","Expects consistent triple-digit revenue growth for remainder of fiscal 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1764110.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}